Silymarin

Silymarin

1. Identity: Botanical Source, Chemical Name, and Nomenclature

Silymarin is not a single compound but rather a polyphenolic flavonolignan complex extracted from the seeds (technically the fruits) of Silybum marianum (L.) Gaertn., the plant commonly known as milk thistle. Silybum marianum is a flowering plant native to the Mediterranean and is particularly renowned for its longstanding use in liver-related disorders. The plant belongs to the family Asteraceae and its extracts are widely used as dietary supplements due to anti-inflammatory, antitumor, and hepatoprotective effects.

The genus name Silybum was designated by the ancient Greek physician Dioscorides, while the species name marianum derives from Christian legend, in which drops of the Virgin Mary's milk fell upon thistle leaves, leaving distinctive white markings. The plant is also known by a range of common names including cardus marianus, blessed milkthistle, Marian thistle, Mary thistle, Saint Mary's thistle, Mediterranean milk thistle, variegated thistle, and Scotch thistle. This fairly typical thistle has red to purple flowers and shiny pale green leaves with white veins.

The crude commercial product of milk thistle is termed silymarin, a complex of at least 7 flavonolignans and 1 flavonoid that comprises 65% to 80% of milk thistle extract. The main components of lipophilic extracts of milk thistle seeds are flavonoids and flavonolignans including silybin A, silybin B, isosilybin A, isosilybin B, silydianin, silychristin, taxifolin, and 2,3-dehydrosilybins. In standardized preparations, the complex includes approximately 70–80 percent silymarin flavonolignans and the remaining 20–30 percent consists of a chemically undefined fraction comprised of polymeric and oxidized polyphenolic compounds.

Silybin is the most abundant and active component of the silymarin complex. Silibinin (INN) is a semipurified fraction derived from silymarin, once thought to be a single compound but now recognized as a 1:1 mixture of two diastereoisomers, silybin A and silybin B. The distinction between silymarin and silibinin is not only important to understanding the historical literature, but thorough characterization and use of chemically defined mixtures in preclinical and clinical studies are essential to the progress of these botanical compounds as human therapeutics.

Most flavonolignans in silymarin are constitutional isomers with the molecular formula C₂₅H₂₂O₁₀. Silymarin belongs to a subclass of plant-based compounds called flavonolignans, which are part of the larger flavonoid family. The seeds contain the highest concentration of silymarin, including its major isomers silybin A and silybin B, along with isosilybin A, isosilybin B, silydianin, silychristin A, silychristin B, and taxifolin.

2. Traditional and Historical Use

Historical records trace the medicinal use of milk thistle back over 2,000 years. Theophrastus (371–287 BC) was the first to mention milk thistle as Pternix, showing its long history of medicinal use. Both Pliny the Elder and Dioscorides described its uses in their works. The Roman naturalist Pliny the Elder, writing in his Naturalis Historia, reportedly recommended the plant for liver ailments.

For centuries, silymarin has been used extensively in traditional medicine throughout Europe and beyond, historically being prescribed for jaundice and a number of hepatobiliary conditions. In cases of food poisoning caused by hepatotoxic fungi, particularly Amanita species, preparations of milk thistle seeds were utilised as an antidotal remedy. Various plant parts were used for a variety of therapeutic purposes in traditional European folk medicine; the aerial parts were advised for uterine disorders, dropsy, and intermittent fevers.

By the 16th century, milk thistle was recognized as an effective remedy for liver and gallbladder disorders. Nicholas Culpeper noted silymarin's effectiveness for treating blockages in the spleen and liver. In medieval times, monks in monastic gardens cultivated it as a staple of their medicinal herb collections, using it to treat everything from jaundice to digestive issues.

Historically, milk thistle fruits were roasted and used as a coffee substitute; flower heads were prepared like artichokes and leaves were used in salads or as a spinach alternative; while in European folk medicine, roots, bark, leaves, and immature fruits were employed to treat gastroenteritis, diarrhea, and dysentery.

Early European colonists brought milk thistle to the Americas, and by the early 20th century, herbalists used it to treat issues related to the kidneys, liver, spleen, and menstruation. Traditional Chinese Medicine incorporated the herb for clearing heat and toxins from the body. Historically, milk thistle was also used to increase breast milk production.

This long history of traditional use laid the groundwork for modern scientific investigation, which began in earnest in the 1960s when German researchers isolated silymarin and started studying its hepatoprotective properties.

From a regulatory standpoint, in 2018, the European Medicines Agency published an assessment report on the oral use of milk thistle fruit and its extracts in EU states, finding that there is a "well-established use" of hepatoprotection approved by 11 countries and a "traditional use" of dyspeptic complaints in 4 countries. The European Medicines Agency (EMA/HMPC) recognises certain milk thistle seed preparations for traditional use in the relief of digestive discomfort, based on long-standing, widespread use across Europe; traditional use recognition is not the same as a clinical disease claim, but it does reflect decades of accepted botanical practice backed by regulatory review.

3. Key Constituents and Active Compounds

The major individual flavonolignans in silymarin have distinct pharmacological profiles. Silymarin, a polyphenolic flavonolignan complex, has long been recognized for its hepatoprotective, antioxidant, anti-inflammatory, and anticancer properties; among its constituents, silybin is the most pharmacologically active and has been extensively studied in both preclinical and clinical settings.

• Silybin (Silibinin): The major active constituent of silymarin; silibinin itself is a mixture of two diastereomers, silybin A and silybin B, in approximately equimolar ratio.
• Isosilybin A and Isosilybin B: Diastereomeric pair also present in significant quantities in the complex.
• Silychristin A and B: Additional flavonolignans contributing to the overall bioactivity of the complex.
• Silydianin: A flavonolignan isomer present in the complex.
• Taxifolin: A flavonoid present in the primary extract of milk thistle, along with the flavonolignans and a number of other constituents.

Fourteen volunteers who consumed an extract of milk thistle were found to absorb and metabolize silychristin, silydianin, silybin, and isosilybin isomers, with 31 metabolites identified in urine, monoglucuronides being the most common excreted form, followed by sulphate-glucuronides and diglucuronides.

4. Mechanisms of Action

4.1 Antioxidant Activity

In the modern era, silymarin exhibits potent antioxidant and anti-inflammatory properties; it stabilises cellular membranes, enhances glutathione levels, scavenges reactive oxygen species (ROS), and modulates inflammatory pathways including NF-κB and Nrf2. Maintaining an optimal redox balance in the cell by activating a range of antioxidant enzymes and non-enzymatic antioxidants, mainly via Nrf2 activation, is considered the main driving force of silymarin's antioxidant action.

4.2 Anti-inflammatory Activity

Silymarin activates the Nrf2/ARE pathway, which enhances transcription of phase II enzymes such as heme oxygenase-1, glutathione peroxidase, superoxide dismutase, and catalase, thereby supporting the glutathione pool and limiting reactive oxygen species; in parallel, it suppresses the NF-κB pathway by preventing IκB degradation and nuclear translocation, leading to reduced transcription of pro-inflammatory mediators such as TNF-α, IL-1β, IL-6, COX-2, and iNOS; the convergence of these pathways results in lower oxidative stress, decreased cytokine-driven injury, and protection against apoptosis and necrosis.

4.3 Hepatocellular Mechanisms

Different mechanisms of action of silymarin on hepatocytes include: increasing the regenerative ability of liver cells by enhancing the synthesis of DNA and RNA; altering the structure of the hepatocyte external membrane, preventing entrance of xenobiotics into the cell (as in Amanita mushroom poisoning); scavenging free radicals and increasing cellular glutathione content, leading to inhibition of lipid peroxidation; and modifying the transporters and receptors of cell membranes such as ABC transporters (P-gp), organic anion uptake transporter peptides (OATP), bile salt export pump, and TNF-α-dependent transporters.

Within hepatocytes, silymarin shows a high affinity for membrane-bound and nuclear receptors, including PPAR-α and CAR/PXR, by enhancing the expression of hepatic detoxification enzymes and improving xenobiotic clearance. Its mitochondrial interaction occurs primarily through the stabilisation of mitochondrial membranes and modulation of oxidative phosphorylation, preserving ATP synthesis while preventing cytochrome c leakage and subsequent apoptosis.

4.4 Signalling Pathway Modulation

Mechanistic studies have clarified that silymarin's major bioactive constituents, like silibinin, silydianin, and silychristin, interact with redox-sensitive transcriptional pathways such as Nrf2/ARE and NF-κB, while also influencing metabolic regulators like AMPK and SIRT1. These synergise with receptor-mediated activation of Nrf2 and inhibition of NF-κB, promoting antioxidant defence; moreover, by attenuating MAPK–ERK and PI3K/Akt/mTOR signalling cascades, silymarin reduces oxidative stress, thereby prolonging hepatocellular survival and optimising pharmacokinetic stability through improved metabolic resilience.

4.5 Anti-fibrotic Activity

Existing research reveals that silymarin has potent antioxidant and anti-inflammatory effects, coupled with anti-fibrotic, anti-carcinogenic, neuro-regenerative, and immunomodulatory actions, and has broad therapeutic relevance in both neurological and hepatic disorders.

5. Scientific Evidence by Area of Use

5.1 Liver Disease and Hepatoprotection

The hepatoprotective application of silymarin is the most studied and the one with the longest regulatory history. The hepatoprotective, anti-inflammatory, antioxidant, and anti-fibrotic effects of silymarin have been studied in patients with cirrhosis associated with viral hepatitis, exposure to environmental toxins, alcoholic steatosis, and non-alcoholic steatohepatitis (NASH).

A 2023 systematic review focusing on liver enzyme levels identified 29 studies examining silymarin. Silymarin dosages in these studies ranged from 140 mg to 420 mg, administered for various durations; results revealed that 65.5% of the studies reported reduced liver enzyme levels, 20.7% exhibited no significant change, and 13.8% observed elevated liver enzymes; the review implies a potential advantageous influence of silymarin on liver enzyme levels, but outcome disparities may stem from comorbidities, suboptimal doses, and underlying diseases.

Non-alcoholic steatohepatitis (NASH) / Non-alcoholic fatty liver disease (NAFLD): A trial involving 64 patients with NASH showed substantial reductions in ALT and AST levels after just eight weeks of treatment with 210 mg/day of silymarin. In addition to lowering liver enzyme levels, silymarin has been associated with histological improvements; a double-blind, placebo-controlled trial reported significant reductions in fibrosis scores among patients treated with 700 mg/day of silymarin over 48 weeks, suggesting a potential role in enhancing liver health and slowing NAFLD progression.

A separate randomized, double-blind, placebo-controlled trial conducted in Malaysia enrolled patients with biopsy-proven NASH with a NAFLD Activity Score of 4 or more. Patients were randomized to receive either silymarin 700 mg three times daily or placebo for 48 weeks. An inverse relationship was noted between silymarin use and the progression from fibrosis to cirrhosis.

A US multicenter Phase II trial (the Siliver trial) tested the proprietary standardized preparation Legalon®. Eligible adult patients had liver biopsy showing NASH without cirrhosis; participants were randomized to Legalon® 420 mg, 700 mg, or placebo three times daily for 48 weeks, with the primary endpoint being histological improvement of ≥2 points in NAS; of 116 patients screened, 78 were randomized, with no significant differences in adverse events among the treatment groups.

A systematic review with meta-analysis including six clinical trials showed that silymarin reduced serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in NAFLD patients, but significant variability and methodological differences across available studies prevent the establishment of robust conclusions.

Cirrhosis: A large randomized controlled trial performed in the pre-liver transplantation era indicated that long-term treatment with silymarin may decrease mortality in patients with cirrhosis, mostly in those consuming ethanol.

Hepatitis C: The impact of silymarin on chronic hepatitis B and C has also been investigated; while some studies suggest benefits in improving liver function tests, evidence regarding its direct influence on viral load remains inconclusive. Higher-than-usual-dose silymarin failed to produce a satisfactory anti-hepatitis C virus (HCV) effect in a large randomized controlled trial, possibly because of the poor bioavailability of silymarin, which led to plasma concentrations far below the levels used in in vitro experiments.

Overall liver evidence assessment: There isn't enough high-quality evidence to allow definite conclusions to be reached about the effects of milk thistle on health conditions in people. In most clinical trials, a better definition of endpoints—such as the progression of fibrosis or the reduction of transaminase levels—is needed, and well-designed, double-blind, placebo-controlled studies are still required.

5.2 Amanita Mushroom Poisoning

One of the most clinically established applications of silymarin, particularly its isolated constituent silibinin, is in the treatment of poisoning by Amanita phalloides and related hepatotoxic fungi. Intravenous silibinin (specifically the water-soluble form silibinin-C-2′,3-dihydrogen succinate disodium, trade name Legalon SIL) is approved in Europe for Amanita poisoning. This is distinct from oral silymarin supplementation and represents a formal pharmaceutical application.

5.3 Type 2 Diabetes Mellitus

Results from a small number of studies in people show that milk thistle extracts may help to control blood sugar in people with type 2 diabetes; most of this research was done in Middle Eastern countries, and it is unclear whether the same results would be seen in other parts of the world.

In a systematic review and meta-analysis including five randomized controlled trials and 270 patients, routine silymarin administration was associated with a significant reduction in fasting blood glucose levels (−26.86 mg/dL; 95% CI −35.42–18.30) and HbA1c levels (−1.07; 95% CI −1.73–0.40) and had no effect on lipid profile. Benefits for silymarin on proteinuria and CKD progression are reported in only one small study and are uncertain; being aware of the low quality of the available evidence and elevated heterogeneity of these studies, no recommendation can be made and further studies are needed.

A separate 2021 meta-analysis of seven trials with 350 patients found that silymarin supplementation can decrease fasting blood sugar, hemoglobin A1C, and LDL-cholesterol, but has no effect on total cholesterol or total triglyceride; the available evidence is nonetheless considered insufficient to make firm conclusions.

A triple-blinded randomized controlled clinical trial involving 40 type 2 diabetes patients (25–50 years of age, on stable medication) tested 140 mg of silymarin three times daily for 45 days. Silymarin supplementation led to significant reductions in fasting blood sugar, serum insulin, homeostatic model assessment for insulin resistance, serum triglyceride, and triglyceride-to-HDL cholesterol ratio compared to placebo. However, not all trials have replicated these findings. In one open-label randomized clinical trial, daily consumption of three capsules of 140 mg silymarin for 12 weeks did not show any significant difference on the level of fasting blood sugar or HbA1c.

5.4 Drug-Induced Liver Injury Prevention

Silymarin has been investigated for its ability to prevent liver injury induced by drugs and toxins. A double-blind randomized placebo-controlled trial examined its ability to prevent antituberculosis drug-induced liver injury (DILI). The trial aimed to evaluate the efficacy of silymarin for preventing antituberculosis-drug-induced liver injury in patients with tuberculosis, with tuberculosis patients randomly allocated to receive placebo or silymarin.

A small clinical trial (60 patients) also investigated silymarin's renoprotective potential in cisplatin-based chemotherapy. Sixty patients with malignancy as candidates for cisplatin treatment were randomly enrolled in two equal groups; in the case group, silymarin tablet 140 mg twice daily was administered seven days before cisplatin administration together with cisplatin. This study showed that silymarin can decrease cisplatin nephrotoxicity, supporting its use as prophylaxis in various cisplatin-containing chemotherapy regimens.

5.5 Cancer — Preclinical and Preliminary Clinical Evidence

Abundant evidence has proved the chemo-preventive activity of silymarin against cancer both in vitro and in vivo; silymarin has the ability to modulate apoptosis in vitro and survival in vivo by intervention in the expression of cell cycle regulators and proteins related to apoptosis. Silymarin modulates the imbalance between cell survival and apoptosis through interference with the expressions of cell cycle regulators and proteins involved in apoptosis; it also showed anti-inflammatory as well as anti-metastatic activity.

The protective effects of silymarin and its major active constituent, silibinin, studied in various tissues, suggest a clinical application in cancer patients as an adjunct to established therapies, to prevent or reduce chemotherapy as well as radiotherapy-induced toxicity.

With respect to clinical translation, in one study, a high dose of silibinin (13 g daily) was administered to patients prior to prostatectomy, achieving high plasma concentrations, but nevertheless low levels of silibinin were found in prostate tissue; in an attempt to circumvent this, one group used a silymarin-phosphatidylcholine compound administered orally as a daily dose of 2.8 g for 4 weeks prior to surgery, achieving high levels in human breast cancer tissue—an encouraging signal for a Phase II clinical trial.

In oncology, combinations involving curcumin or vincristine have demonstrated preclinical efficacy against NF-κB-mediated resistance; however, clinical validation has not been conducted. Cancer Research UK stated in 2019: "We need a lot more research with reliable clinical trials before we can be sure that milk thistle will play any part in treating or preventing cancers." Overall, evidence from human clinical trials for cancer indications remains very preliminary.

5.6 Neuroprotection

Apart from the hepatoprotective nature, silymarin has recently been reported to be a putative neuroprotective agent against many neurologic diseases including Alzheimer's and Parkinson's diseases, and cerebral ischemia; the underlying neuroprotective mechanism is believed to be due to its capacity to inhibit oxidative stress in the brain, but it also confers additional advantages by influencing pathways such as β-amyloid aggregation, inflammatory mechanisms, cellular apoptotic machinery, and estrogenic receptor mediation.

Neuroprotective evidence in support of silymarin has been documented not only in animal models of neurodegenerative diseases but also in neuronal and non-neuronal cellular models of Alzheimer's disease, cerebral ischemia, and Parkinson's disease. However, reports on the effect of silymarin on other central nervous system disorders where oxidative stress plays a pivotal role, such as Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis, are lacking. Robust human clinical trials in neurological indications are absent at this time; the available evidence is preclinical.

5.7 Chemotherapy-Associated Complications

A triple-blinded randomized clinical trial evaluated nano-silymarin for the prevention of hand-foot syndrome and neuropathy induced by chemotherapy regimens (XELOX or m-FOLFOX6) in metastatic colorectal cancer. Numerous pre-clinical and clinical studies have examined the effectiveness of silymarin in preventing and treating complications caused by chemotherapeutic agents; however, there is a limited number of well-designed randomized clinical trials on this potential effect of silymarin, and further studies are considered crucial.

6. Dosage Forms and Reported Dosages

6.1 Common Dosage Forms

• Standardized oral capsules/tablets: Modern supplements typically use a standardized extract of milk thistle containing a specific percentage of silymarin (usually 70–80%) to ensure consistent potency and effectiveness.
• Phosphatidylcholine (phytosome) complex: Preparations containing phospholipids such as phosphatidylcholine may increase absorption of silymarin and its silybin constituent. Plasma levels of silybin were significantly higher after the administration of silybin–phosphatidylcholine complex capsules compared with that after conventional silymarin tablets.
• Intravenous formulation: In some European countries, silibinin is available as a water solution containing the dihemisuccinate disodium salt for intravenous injection.
• Dried fruit / teas: Dosage for the dried fruits is 4–9 g and for the liquid extract 1:1 is 4–9 ml.

6.2 Dosages Reported in Clinical Studies

• Dosing regimens in studies range from an equivalence of 140 mg of standardized silymarin daily to 900 mg daily.
• Recommended dosing of silymarin is a range from 70 to 140 milligrams three times per day in various disease conditions.
• In a triple-blinded diabetes trial, patients received 140 mg of silymarin three times daily (420 mg/day) for 45 days.
• A trial involving 64 NASH patients used 210 mg/day of silymarin for eight weeks.
• A double-blind, placebo-controlled fibrosis trial used 700 mg/day of silymarin over 48 weeks.
• A NASH trial randomized patients to receive either silymarin 700 mg three times daily (2,100 mg/day) or placebo for 48 weeks.
• A US multicenter Phase II NASH trial randomized participants to Legalon® 420 mg or 700 mg three times daily for 48 weeks.
• In the cisplatin nephrotoxicity prevention study, silymarin 140 mg twice daily was administered seven days before and during cisplatin administration.
• Silymarin has been shown to be safe for human consumption at therapeutic doses, even in doses of 700 mg three times daily (2,100 mg/day) for up to 24 weeks.
• The Health Canada NHP monograph cites a maximum daily therapeutic dose of 600 mg per day of silymarin, with a further recommended maximum single-dose limit of 200 mg.
• The ESCOP monograph (2009) describes the use of milk thistle fruit for treatment of toxic liver damage and supportive treatment of chronic inflammatory liver conditions, with dosage for the extract corresponding to 165–330 mg silymarin.

7. Pharmacokinetics and Bioavailability

The clinical application of silymarin-based therapies remains limited by poor aqueous solubility, low oral bioavailability, rapid metabolism, and physicochemical instability. Silymarin has oral absorption of only about 23–47% and undergoes quick phase II conjugation, leading to low bioavailability. Silymarin's bioavailability is notably low, averaging about 0.95%, primarily due to poor solubility in water and extensive phase II metabolism.

Orally administered silymarin has a peak concentration (t_max) occurring between 2 and 4 hours and has a half-life of approximately 6 hours; however, only 20–50% of oral silymarin is absorbed from the gastrointestinal tract, where it undergoes extensive enterohepatic circulation. Silymarin undergoes phase I and phase II metabolism, especially phase II conjugation reactions, undergoing multiple conjugation reactions, and is primarily excreted into bile and urine.

After absorption, silymarin undergoes rapid phase II metabolism and is primarily excreted into bile and urine; it exhibits enhanced absorption in patients with hepatitis C and non-alcoholic fatty liver disease. The major efflux transporters of silybin are multidrug resistance-associated protein (MRP2) and breast cancer resistance protein (BCRP).

Clinical trials have shown silymarin is safe at high doses (>1500 mg/day) in humans; however, pharmacokinetic studies over the past three decades related to absorption, distribution, metabolism, and excretion have revealed poor absorption, rapid metabolism, and ultimately poor oral bioavailability. Newer formulation strategies, including phospholipid complexes and nanoparticle-based delivery systems, have been developed to address this limitation. Nanocarriers are a promising solution to silymarin's low solubility and limited bioavailability, aiming to enhance targeted delivery to the central nervous system and hepatic tissue.

8. Safety Considerations and Drug Interactions

8.1 General Safety Profile

Toxicological studies have shown that tolerability of silymarin is suitable, and its adverse effects are mainly limited to negligible allergic reactions, gastrointestinal disorders, headache, nausea, itching, and urticaria. In human and animal studies, silymarin has shown no specific serious side effects; in rare cases, its use has been associated with gastrointestinal symptoms, headaches, confusion, and skin reactions.

Very few side effects from the use of milk thistle or silymarin have been reported; several large studies in patients with liver disorders have found that taking silymarin may rarely have a laxative effect or cause nausea, heartburn, or stomach upset; at high doses, mild allergic reactions have been seen.

8.2 Allergic Reactions

Milk thistle may cause allergic reactions, particularly among people who are allergic to related plants (for example, ragweed, chrysanthemum, marigold, and daisy).

8.3 Drug Interactions

Clinical trial data concluded that silymarin does not pose a clinically relevant risk of drug–drug interaction; although silymarin does inhibit activities of enzymes and transporters concerned with the pharmacokinetics of therapeutic drugs, its concentration within the human body rarely reaches the point that constitutes significant inhibition due to low bioavailability; however, exceptions do exist.

Silymarin has limited effect on the pharmacokinetics of several drugs in vivo, despite decreasing the activity of cytochrome P-450 (CYP) enzymes, UDP-glucuronosyltransferase (UGT) enzyme, and reducing P-glycoprotein (P-gp) transport. In vitro, the enzymes most commonly flagged for potential inhibition include CYP3A4 and CYP2C9, and silymarin may also affect P-glycoprotein transporter function.

Oral administration of silibinin at daily doses up to 1.44 g over a week has been established as safe in clinical studies.

8.4 Product Quality Concerns

Concerns have been raised about poor chemical and microbiological quality of milk thistle dietary supplements sold in the United States and other countries; some products have been found to contain amounts of silymarin substantially different from what's stated on the label, or to be contaminated with pesticides, microorganisms, or mycotoxins.

8.5 Regulatory Status

The U.S. Food and Drug Administration (FDA) has not approved the use of milk thistle as a treatment for cancer or any other medical condition. In the United States, silymarin/milk thistle is sold as a dietary supplement and is not subject to the same pre-market approval requirements as pharmaceutical drugs. As noted, in Europe, intravenous silibinin dihemisuccinate disodium (Legalon SIL) carries specific approval for Amanita phalloides poisoning in several countries.

References

• NCCIH (National Center for Complementary and Integrative Health) — Milk Thistle: Usefulness and Safety
• Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications — Frontiers in Pharmacology / PMC (2025)
• Frontiers in Pharmacology — Silymarin as a phytopharmaceutical agent (full text, 2025)
• Journal of the American Society for Mass Spectrometry — Chemical Standardization of Milk Thistle Extract Using UHPLC-MS/MS
• Frontiers in Sustainable Food Systems — Exploring the chemical composition, antioxidant, and antibacterial properties of milk thistle (2025)
• Pharmaceutics (MDPI) — Silymarin and Silybin: Rejuvenating Traditional Remedies with Modern Delivery Strategies (2025)
• PMC — Silymarin as an Antioxidant Therapy in Chronic Liver Diseases: A Comprehensive Review (2024)
• PMC / Trials — Efficacy of silymarin in patients with NAFLD — the Siliver trial (2023)
• Clinical Gastroenterology and Hepatology — A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis (2017)
• PMC — Silymarin in non-cirrhotics with NASH: A randomized, double-blind, placebo-controlled trial
• PMC — Silymarin in the treatment of liver diseases: What is the clinical evidence?
• PMC — Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2016)
• ScienceDirect — The effects of silymarin on type 2 diabetes mellitus: A systematic review and meta-analysis (2021)
• PubMed — The effects of silymarin supplementation on metabolic status and oxidative stress in patients with T2DM: A systematic review and meta-analysis (2018)
• PubMed — Lower glycemic indices and lipid profile among type 2 diabetes patients receiving silymarin extract supplement: A Triple-blinded RCT
• Antioxidants (MDPI) — Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
• Molecules (MDPI) — Metabolism, Transport and Drug–Drug Interactions of Silymarin
• PMC — Metabolism, Transport and Drug–Drug Interactions of Silymarin
• ScienceDirect — Drug–drug interactions of silymarin on the perspective of pharmacokinetics
• PMC — Neuroprotective Potential of Silymarin against CNS Disorders: Insight into the Pathways and Molecular Mechanisms of Action
• PMC / NIH — Multitargeted therapy of cancer by silymarin
• ScienceDirect — Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid (2023)
• PMC — Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
• PMC — Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy (2025)
• PMC — Effect of Silymarin in the Prevention of Cisplatin Nephrotoxicity, a Clinical Trial Study
• PMC — A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury
• PubMed — Reassessing bioavailability of silymarin
• PMC — Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets
• PMC — Analgesia and silymarin: What are the opportunities and challenges? (2025)
• PMC — Impact of Silymarin Supplements on Liver Enzyme Levels: A Systematic Review (2023)
• PMC — "Silymarin", a Promising Pharmacological Agent for Treatment of Diseases
• European Medicines Agency — Final Assessment Report on Silybum marianum (L.) Gaertn., fructus
• Health Canada — Safety assessment of milk thistle seed extract (silymarin) as a supplemental ingredient
• Wikipedia — Silibinin
• Nutrients (MDPI) — Hepatoprotective Effect of Silymarin Herb in Prevention of Liver Dysfunction Using Pig as Animal Model (2025)
• NCCIH — Hepatitis C and Dietary Supplements: What the Science Says